09:51 AM EST - Sernova Corp. : Announced today that the European Commission's Horizon 2020 program has awarded a EUR5.6-million ($8.5-million Canadian) grant to a consortium consisting of Sernova Corp. and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova's Cell Pouch™ for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream. Sernova Corp.
shares V.SVA are trading down $0.005 at $0.32.
